Compounds / Tirzepatide
Metabolic MounjaroZepbound

Tirzepatide

A dual GIP/GLP-1 receptor agonist developed by Eli Lilly showing the largest weight loss results of any peptide therapeutic in clinical trials to date.

Overview

Tirzepatide is a 39-amino-acid synthetic peptide developed by Eli Lilly that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual mechanism distinguishes it from semaglutide (GLP-1 only) and represents a novel therapeutic approach to metabolic disease. FDA-approved in 2022 for type 2 diabetes (Mounjaro) and 2023 for chronic weight management (Zepbound), tirzepatide has produced the largest weight reduction data points of any approved peptide therapeutic — the SURMOUNT-1 trial reported mean weight loss of up to 22.5% of body weight at the 15 mg dose.

Mechanism

Tirzepatide's "twincretin" mechanism involves co-activation of GIP and GLP-1 receptors. GIP receptor agonism is believed to enhance insulin secretion, improve insulin sensitivity in adipose tissue, reduce glucagon levels, and complement GLP-1 receptor signaling. The synergy between the two pathways produces greater glucose lowering and weight reduction than selective GLP-1 agonism alone. Additionally, tirzepatide activates GIP receptors in adipose tissue directly, which may contribute to its superior fat mass reduction profile.

Research Areas

Type 2 diabetes glycemic controlObesity and weight managementNon-alcoholic fatty liver diseaseCardiovascular and renal outcomes (ongoing SURPASS/SURMOUNT trials)Heart failure with preserved ejection fraction (SUMMIT trial)

Side Effects (Preclinical)

  • – Nausea, vomiting, diarrhea (most common; dose-dependent)
  • – Decreased appetite
  • – Injection-site reactions
  • – Rare: pancreatitis, gallbladder events

Cautions

  • – Research-grade tirzepatide is not pharmaceutical-grade Mounjaro/Zepbound — for laboratory research only
  • – Contraindicated (per labeling) in medullary thyroid carcinoma history
  • – Active area of regulatory scrutiny for compounding pharmacies

Menopause & Women's Health Relevance

The SURMOUNT-1 trial (majority female cohort) showed up to 22.5% mean weight loss — greater than semaglutide in head-to-head data. GIP receptor agonism may have additional relevance at menopause: GIP receptors are expressed in bone, and early data suggests tirzepatide may have favorable effects on bone density that semaglutide does not share — important given accelerated bone loss post-menopause.

weight gaininsulin resistancemetabolic changesvisceral fatbone health
See all menopause-relevant compounds →

What the research shows

SURMOUNT-1 (Jastreboff et al., 2022) reported mean weight reductions of 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses respectively over 72 weeks, with 22.5% in a completers analysis. These are the largest placebo-controlled weight loss results published for any approved pharmacological intervention as of 2026.

The SURPASS-2 head-to-head against semaglutide 1 mg (Frías et al., 2021) showed tirzepatide superior on both HbA1c reduction and weight loss at all three doses tested.

References

Related Compounds

semaglutide retatrutide